The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

Bayer has joined its peers among European drugmakers ... There were also modest gains for the company's consumer health and crop science divisions, although restructuring costs dragged down ...

Berlin: Bayer and Suzhou Puhe BioPharma Co., Ltd., a clinical-stage biotechnology company, have announced that they have ...

Bayer is a member of the Critical Medicines Alliance ... 2022 under the EU’s Better Regulation principles. Swiss pharma company Roche also considered the lack of an impact assessment “a ...

The company is due to set out progress ... they are not as profitable as Xarelto. Bayer’s Xarelto blood thinner medicine once accounted for more than 10% of the pharmaceutical division’s ...

(Bloomberg) — Bayer AG forecast a third straight year of falling profit as the German company struggles with mass litigation in the US, slumping prices for agriculture products and fresh competition ...

Bayer obtains exclusive worldwide license for MTA-cooperative PRMT5 inhibitor for selective targeting of MTAP-deleted tumors ...

Bayer, Puhe BioPharma ink global license agreement for clinical phase I PRMT5 inhibitor: Berlin, Germany Friday, March 28, 2025, 13:00 Hrs [IST] Bayer and Suzhou Puhe BioPharma Co ...

Bayer and Suzhou Puhe BioPharma Co. Ltd., a clinical-stage biotechnology company, on Wednesday announced ... by our ambition to develop innovative medicine that will improve and extend the lives ...